Vivo Ventures

Vivo Capital is a global healthcare specialist investment firm, strategically deploying capital across the healthcare landscape. It utilizes a multi-strategy platform, integrating venture capital, private equity, and public equity, with emphasis on biopharma, medical devices, diagnostics, digital health, and healthcare services. The firm identifies and cultivates high-quality companies within the U.S. and Chinese markets, fostering innovation and growth in medicine.

The firm was established in 1996 by Frank Kung and Edgar G. Engleman, both seasoned experts in biotech and medicine. Their foundational insight originated from prior experience building the biotech company Genelabs, where Kung served as CEO and Engleman as Chief Scientific Officer. This direct operational background in life sciences informed their transition to an investment strategy, leveraging deep industry knowledge to back promising healthcare ventures.

Vivo Capital’s portfolio companies span healthcare innovation. The firm’s mission is to drive medical advancements by partnering with and funding enterprises dedicated to addressing significant unmet medical needs globally. Through strategic capital, Vivo Capital aims to continuously improve patient care and health outcomes worldwide.